Peptide Dosing Chart for Retatrutide: What the Research Shows

There is no FDA-approved peptide dosing chart for retatrutide, because retatrutide is an investigational drug that has not been authorized for human use outside of clinical trials. The only dosing information that comes from controlled research is the once-weekly subcutaneous schedule used in Eli Lilly's phase 2 trial, where participants received 1 mg, 4 mg, 8 mg, or 12 mg with a stepwise increase. Any chart marketed as a consumer dosing guide for retatrutide is not based on approved labeling.

What Retatrutide Is and Why Its Dosing Chart Is Different

Retatrutide is a synthetic triple receptor agonist that activates GLP-1, GIP, and glucagon receptors at the same time. That three-receptor mechanism separates it from semaglutide, which targets GLP-1 only, and from tirzepatide, which targets GIP and GLP-1.

Because retatrutide is still in phase 3 development, there is no package insert, no approved indication, and no official dose. Researchers publish trial protocols instead of prescribing information, so a retatrutide chart summarizes study design rather than a treatment plan.

Compounds sold as a retatrutide research peptide for sale are typically manufactured for laboratory use and are not the same as a pharmaceutical product reviewed by the FDA. Purity, sterility, and actual content are not guaranteed in that market.

Retatrutide Dosing Schedule Used in Clinical Trials

The phase 2 trial published in the New England Journal of Medicine in 2023 randomized adults with obesity but without diabetes to placebo or retatrutide for 48 weeks. Doses started low and escalated about every four weeks to limit gastrointestinal side effects.

Trial dose group	Starting dose	Escalation step	Maintenance dose	Schedule
1 mg	1 mg	None	1 mg	Once weekly, subcutaneous
4 mg	2 mg	2 mg after 4 weeks	4 mg	Once weekly, subcutaneous
8 mg	2 mg	2 mg every 4 weeks	8 mg	Once weekly, subcutaneous
12 mg	2 mg	2 mg every 4 weeks	12 mg	Once weekly, subcutaneous

These numbers describe research groups, not recommended doses. A trial protocol cannot be translated into safe self-administration, and no medical organization has endorsed a retatrutide dose for general use.

Why Titration Matters in Any Retatrutide Dosing Plan

Nausea, vomiting, diarrhea, and constipation are the most common effects reported in the retatrutide trials, and they cluster in the weeks after each dose increase. Slower escalation is the standard strategy across GLP-1 class drugs to reduce those symptoms.

• Begin at the lowest tolerated dose in the protocol.
• Hold each step for at least four weeks before increasing.
• Pause escalation if side effects are moderate or persistent.
• Reduce the next step rather than pushing through symptoms.

The same logic drives the peptide dosing chart tirzepatide users see, where 2.5 mg weekly is held for four weeks before moving to 5 mg.

Retatrutide vs. Other GLP-1 and GIP Dosing Charts

Compound	Regulatory status	Studied or approved dose range	Frequency
Retatrutide	Investigational, not FDA-approved	1 mg to 12 mg (phase 2)	Once weekly
Tirzepatide	FDA-approved	2.5 mg to 15 mg	Once weekly
Semaglutide	FDA-approved	0.25 mg to 2.4 mg	Once weekly
Liraglutide	FDA-approved	0.6 mg to 3 mg	Once daily

Maximum doses differ because each molecule has a different potency and receptor profile. A larger milligram number on a chart does not mean a stronger or better result for an individual.

How to Read a Research Peptide Dosing Chart

Many people searching for a peptide dosing chart pdf want a single reference sheet listing vial size, reconstitution volume, and syringe units. Those sheets are useful for recording measurements, but they do not validate the substance being measured.

1. Check whether the chart cites a clinical trial or only a vendor.
2. Confirm that units such as mg, mcg, and mL are labeled clearly.
3. Look for a clear separation between approved drugs and research chemicals.
4. Expect titration steps and side-effect guidance, not just a number.

Charts for unrelated compounds, such as an aod-9604 peptide dosing chart or a klow peptide dosing chart, follow a similar format of dose, frequency, and volume. Shared layout does not mean shared safety data or approval status.

Safety, Side Effects, and Legal Status

Retatrutide is not FDA-approved for human use in the United States. Buying it outside a clinical trial means obtaining an unapproved, unregulated substance, and the FDA has warned that research-grade peptides often carry inaccurate labels.

Side effects reported in trials included nausea, diarrhea, vomiting, constipation, and increased heart rate. Gallbladder and pancreatic events have been reported with GLP-1 class drugs, and rapid weight loss can reduce lean muscle mass.

Anyone considering a GLP-1 or triple agonist should talk with a licensed healthcare professional about approved options, drug interactions, and monitoring. Self-dosing from an internet chart carries real risk of overdose, infection, and unmonitored complications.

Bottom Line on the Retatrutide Peptide Dosing Chart

The only reliable retatrutide dosing data comes from clinical trials that used 1 mg to 12 mg once weekly with gradual escalation. No consumer dosing chart has been reviewed or approved by any regulator, and retatrutide remains an investigational drug.

If you need a dose reference for an approved medication, use the manufacturer's prescribing information or the guidance of a licensed clinician instead of a chart from a peptide vendor.

COMMON QUESTIONS

Frequently Asked Questions

Is there an official retatrutide dosing chart?

No. Retatrutide is not FDA-approved, so there is no official or recommended dosing chart for human use. The only published dose information comes from clinical trials that studied 1 mg to 12 mg given once weekly under medical supervision.

What dose of retatrutide was studied in clinical trials?

The phase 2 trial tested 1 mg, 4 mg, 8 mg, and 12 mg given once weekly by subcutaneous injection over 48 weeks. Each group escalated the dose roughly every four weeks to reduce gastrointestinal side effects. These were research doses, not treatment recommendations.

Can you legally buy retatrutide peptides online in the US?

Retatrutide is not approved for human use, so products sold online as research chemicals are not legal for human consumption and are not quality-verified. The FDA has warned that these peptides may be mislabeled, contaminated, or incorrectly dosed. Anyone seeking weight-management treatment should consult a licensed healthcare professional about approved options.